Fierce Biotech August 26, 2024
MBX Biosciences has added to the recent flurry of IPO filings. The biotech, which filed its paperwork weeks after raising $63.5 million privately, is seeking funding to take a would-be challenger to Ascendis Pharma’s rare endocrine disease drug Yorvipath into phase 3 development.
Indiana-based MBX is built on technology designed to address the limitations of both unmodified and modified peptide therapies. By engineering peptides to improve their druglike properties, the biotech is trying to reduce the frequency of dosing, ensure consistent drug concentrations and otherwise establish product characteristics that improve clinical outcomes and simplify the management of diseases.
MBX used the platform to create the hypoparathyroidism candidate MBX 2109. The biotech is trying to provide continuous exposure to parathyroid hormone...
Today's Sponsors
Today's Sponsor